亿帆医药
(002019)
| 流通市值：79.11亿 | | | 总市值：114.22亿 |
| 流通股本：8.43亿 | | | 总股本：12.16亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,255,507,032.81 | 5,132,949,329.53 | 3,922,709,366.04 | 2,635,110,083.18 |
| 营业收入 | 1,255,507,032.81 | 5,132,949,329.53 | 3,922,709,366.04 | 2,635,110,083.18 |
| 二、营业总成本 | 1,119,394,963.51 | 4,696,113,393.72 | 3,507,090,512.56 | 2,316,453,207.97 |
| 营业成本 | 680,092,909.85 | 2,726,658,411.63 | 2,046,852,839.24 | 1,355,113,404.41 |
| 税金及附加 | 13,621,186.25 | 49,565,259.72 | 38,283,518.03 | 26,816,307.83 |
| 销售费用 | 260,603,221.36 | 1,158,279,825.87 | 911,396,543.31 | 620,586,202.68 |
| 管理费用 | 91,545,148.51 | 418,038,567.63 | 284,315,519.78 | 180,754,339.09 |
| 研发费用 | 54,373,794.29 | 291,374,013.55 | 191,866,180.76 | 118,627,834.42 |
| 财务费用 | 19,158,703.25 | 52,197,315.32 | 34,375,911.44 | 14,555,119.54 |
| 其中:利息费用 | 11,753,271.77 | 53,039,094.91 | 42,365,805.07 | 25,822,154.1 |
| 其中:利息收入 | 2,639,862.16 | 12,063,797.58 | 7,897,184.85 | 5,452,211.74 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -50,854.58 | -143,103.71 | -250,625.62 | -459,827.92 |
| 加:投资收益 | -4,606,820.96 | -27,309,932.03 | -22,725,516.58 | -14,370,446.64 |
| 资产处置收益 | 20,032.18 | 12,695,234.82 | 10,132,477.36 | 3,858,234.66 |
| 资产减值损失(新) | -7,485,581.85 | -58,977,847.99 | -16,001,135.53 | -11,333,286.25 |
| 信用减值损失(新) | -9,286,668.26 | -22,667,053.73 | -28,310,577.33 | -23,146,737.3 |
| 其他收益 | 5,365,090.25 | 88,211,656.63 | 77,243,373.06 | 69,741,135.46 |
| 四、营业利润 | 120,067,266.08 | 428,644,889.8 | 435,706,848.84 | 342,945,947.22 |
| 加:营业外收入 | 884,331.8 | 5,469,729.5 | 2,831,097.27 | 2,571,952.61 |
| 减:营业外支出 | 89,118.03 | 10,410,381.84 | 3,726,977.38 | 1,193,751.91 |
| 五、利润总额 | 120,862,479.85 | 423,704,237.46 | 434,810,968.73 | 344,324,147.92 |
| 减:所得税费用 | 25,149,756.01 | 50,252,508.22 | 74,558,949.74 | 60,166,012.1 |
| 六、净利润 | 95,712,723.84 | 373,451,729.24 | 360,252,018.99 | 284,158,135.82 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 95,712,723.84 | 373,451,729.24 | 360,252,018.99 | 284,158,135.82 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 106,827,242.39 | 402,021,183.61 | 387,786,703.89 | 303,651,052.46 |
| 少数股东损益 | -11,114,518.55 | -28,569,454.37 | -27,534,684.9 | -19,492,916.64 |
| 扣除非经常损益后的净利润 | 104,102,343.54 | 324,793,078.29 | 315,399,316.03 | 237,210,048.08 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.33 | 0.32 | 0.25 |
| (二)稀释每股收益 | 0.09 | 0.33 | 0.32 | 0.25 |
| 八、其他综合收益 | -45,377,158.2 | 29,928,782.62 | 40,735,013.03 | 61,055,565.28 |
| 归属于母公司股东的其他综合收益 | -45,343,551.63 | 29,732,504.94 | 40,570,592.37 | 61,155,138.74 |
| 九、综合收益总额 | 50,335,565.64 | 403,380,511.86 | 400,987,032.02 | 345,213,701.1 |
| 归属于母公司股东的综合收益总额 | 61,483,690.76 | 431,753,688.55 | 428,357,296.26 | 364,806,191.2 |
| 归属于少数股东的综合收益总额 | -11,148,125.12 | -28,373,176.69 | -27,370,264.24 | -19,592,490.1 |
| 公告日期 | 2026-04-24 | 2026-04-24 | 2025-10-31 | 2025-08-15 |
| 审计意见(境内) | | 标准无保留意见 | | |